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• > 3 months of renal dysfunction
• Albuminuria
• Urine sediment abnormalities
• Electrolyte abnormalities
• Histologic abnormalities
• Imaging structural abnormalities
• Prior renal transplant
Chronic Kidney Disease (CKD)
Most Common 
Comorbidities
Diabetes Mellitus
Cardiovascular Disease
NKF https://www.kidney.org/atoz/content/gfr
• When is dialysis 
initiated?
• Signs and symptoms 
of uremia and 
volume overload
CKD to ESRD
Encephalopathy*
Pericarditis*
Pleuritis*
Declining nutrition
Refractory volume overload
Fatigue and malaise
Mild cognitive impairment
Refractory acidosis, hyperK+, hyperphos
*absolute indications
Incidence of ESRD in US (1980-2016)
Data Source: Special analyses, USRDS ESRD Database. The special analyses exclude US territories, unknown age, and 
unknown/other races. Standardized to the age-sex-race distribution of the 2011 US population.
Prevalence of ESRD in US (1980-2016)
Data Source: Special analyses, USRDS ESRD Database. Standardized to the age-sex-race distribution 
of the 2011 US population. 
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Renal replacement therapy - Transplant
Data Source: Reference Table D.1 and special analysis of USRDS ESRD Database. 
Abbreviation: ESRD, end-stage renal disease. 
Renal replacement therapy - Transplant
Data Source: Reference Table D.10 and special analyses, USRDS ESRD Database. 
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Renal replacement therapy – PD
USRDS ESRD Database (2019) Reference Table D.1
Peritoneal Dialysis
• 200,000 patients worldwide
• Given an informed choice, 
50% of patients will choose 
PD first
Jain AK, Blake P, Cordy P, 
Garg AX. Global trends in 
rates of peritoneal dialysis. J 
Am Soc Nephrol. 
2012;23(3):533-544. 
doi:10.1681/ASN.2011060607
USRDS 2017
Renal replacement therapy - PD
Data Source: Reference Table D.10 and special analyses, USRDS ESRD Database. The numbers 
in this table exclude “Uncertain Dialysis.”
PREVALENT ESRD
Peritoneal Dialysis
Peritoneal Dialysis
Peritoneal Membrane
Peritoneal Capillary
• Peritoneal capillary is critical 
barrier to solute and water 
transport
• BF ~ 50-100 mL/min
Peritoneal Capillary
4-6 nm
(numerous)
>20 nm
(1 gap: 10,000 clefts)
0.4 - 0.6 nm
(numerous)RBC 6-8 μm
(6000-8000 nm)
Methods of Peritoneal Clearance
• Diffusion (solutes)
• Ultrafiltration (water)
• Convection (solutes)
Methods of Peritoneal Clearance
• Diffusion (solutes)
• Solutes travel down a 
concentration gradient
• Via small and large pores
• Ultrafiltration (water)
• Convection (solutes)
Methods of Peritoneal Clearance
• Diffusion (solutes)
• Ultrafiltration (water)
• H2O movement due to 
differences in osmotic
pressure
• Via small pores, large pores, 
and aquaporins
• Convection (solutes)
Capillary 
membrane
Blood Diasylate
H2O
Methods of Peritoneal Clearance
• Diffusion (solutes)
• Ultrafiltration (water)
• Convection (solutes)
• “Solvent drag”
• As H2O moves, other solutes 
move too
• Independent of solute 
concentration gradients
All shapes and sizes
All shapes and sizes
Who places PD catheters?
Surgeon → Laparoscopy
Interventional Radiology → Fluoroscopic + US Guidance
Interventional Nephrology → US Guidance
Technique for IR placement
Technique for IR placement
Technique for IR placement
Technique for IR placement
Technique for IR placement
Technique for IR placement
Catheter Positioning 
Peritoneal Dialysis Prescriptions
• Continuous Ambulatory Peritoneal 
Dialysis (CAPD)
• No machine needed
• 24/7
Types of PD Rx
• Automated Peritoneal Dialysis (APD)
• Continuous Cycling Peritoneal 
Dialysis (CCPD)
• Machine run cycles
• 7 d/wk
Hodges JC, Fi llinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access 
methods: ri sk factors for failure. J Vasc Surg. 1997;26:1009-1019.
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Renal replacement therapy
Data Source: Reference Table D.1 and special analysis of USRDS ESRD Database. 
Renal replacement therapy
Data Source: Reference Table D.10 and special analyses, USRDS ESRD Database.
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Catheter-Based Hemodialysis
• Benefits
• Rapid start
• Quick and easy to place
• Functional
• Easily removed if renal recovery
• Multiple placement options
Catheter-Based Hemodialysis
• Negatives
• High associated morbidity and 
mortality 
• Infection
• Hospitalization
• Death
• Accelerated vascular injury →
lost access
Vascular access use at HD initiation
Data Source: Special analyses, USRDS ESRD Database. ESRD patients initiating hemodialysis in 2005-2017. 
Hemodialysis access over time
Data Source: Special analyses, USRDS ESRD Database. Data from January 1, 2014 to May 30, 2017: (a) Medical 
Evidence form (CMS 2728) at initiation and CROWNWeb for subsequent time periods. (b) ESRD patients 
initiating hemodialysis (N =104,102). 
Change in HD access over time
Data Source: Special analyses, USRDS ESRD Database. Data from January 1, 2014 to May 30, 2017: (a) 
Medical Evidence form (CMS 2728) at initiation and CROWNWeb for subsequent time periods. (b) ESRD 
patients initiating hemodialysis (N =104,102). 
Fistula First Breakthrough Initiative → Fistula First/Catheter Last (2009)
• Goal: 66% national prevalent AVF 
use
• Resulted in a steady increase in 
the prevalence of AVF
• 32% (2003) → 63% (2014)
• Goal: reduce long-term tunneled 
catheter use 
• Not including bridging catheters
• Has not been as successful
• AVFs associated with lowest 
morbidity
• Higher primary patency
• Lower risk of infection
• Better durability
• Lower associated mortality
• Require fewer interventions
• Grafts have their place
• Comparable secondary patency 
rates
• Potentially a better option in 
older patients
ESRD
Dialysis
Hemo-
Catheter Fistula Graft
Peritoneal
Transplant
Renal replacement therapy
Fistula versus Graft
AV FISTULA AV GRAFT
PTFE
Graft material
A: DACRON - https://digital.sciencehistory.org/works/1c18dg840
B: PTFE https://www.news-medical.net/FUSION-BIOLINE-Vascular-Grafts-from-Maquet
DACRON
Graft material
https://radiologykey.com/graft-surveillance-and-preoperative-vein-mapping-for-bypass-
surgery/
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• Dember LM, et al (JAMA, 2008)
• Randomized, double-blind, 
placebo controlled, multicenter
• Of 758 patients, 60% of fistulas 
failed to be suitable for HD
• Woodside KJ, et al (AJKD, 2018)
• Observational cohort study
• USRDS Medicare claims data
• 54.7% of fistulas used within 4 
months of creation
• Hemodialysis Fistula Maturation 
Study
• 602 AVFs
• 43.7% matured unaided
• 27.6% matured with intervention
• 22.1% failed maturation 
completely
Poor maturation of surgical AVFs
Technical factors
• Disruption of the vasa 
vasorum
• Torque and tension on the 
mobilized vessel
• Healing suture anastomoses 
can lead to scarring, 
intimal hyperplasia, and 
stenosis
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Technical factors
• Disruption of the vasa 
vasorum
• Torque and tension on the 
mobilized vessel
• Healing suture anastomoses 
can lead to scarring, 
intimal hyperplasia, and 
stenosis
Browne, Leonard & Bashar, Khalid & Griffin, Philip & Kavanagh, Eamon & Walsh, Stewart & Walsh, Michael. 
(2015). The Role of Shear Stress in Arteriovenous Fistula Maturation and Failure: A Systematic Review. PloS
one. 10. e0145795. 10.1371/journal.pone.0145795. 
Technical factors
• Disruption of the vasa 
vasorum
• Torque and tension on the 
mobilized vessel
• Healing suture anastomoses 
can lead to scarring, 
intimal hyperplasia, and 
stenosis
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Traumatic AVFs
Mulatti, Grace Carvajal, et al. “Traumatic Arteriovenous Fistula.” Arteriovenous Fistulas Diagnosis and Management, 2013.
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Deep vessels
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Radial artery + vein
Interosseous artery + vein
Ulnar artery + vein
Deep vessels
Brachial artery + 
paired veins
Ulnar artery + 
paired veins
Interosseous artery + 
paired veins
Radial artery + paired veins
Deep vessels
Superficial veins
Brachial artery + 
paired veins
Ulnar artery + 
paired veins
Interosseous artery + 
paired veins
Radial artery + paired veins
Basilic vein
Cephalic vein
Perforating vein
Median cubital vein
Perforating vein
Perforating vein
Perforating vein
Percutaneous AVF devices
Percutaneous AVF devices - Ellipsys
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Perforating vein
Radial artery
Percutaneous AVF devices - Comparison
• Post balloon angioplasty to 5 mm
• Immediate tissue fusion
• Coil 1 brachial vein
• Endothelialized tract ~30d (48h)
Author (Year) Device # pts
Technical 
success
Maturation 
90d
Median time to 
maturation
Mean time to 2 
needle cann
Patency
Hull (2017) E 107 95% 86% 114.3 d 86.7% 24m, 
cum
Hebibi
(2019)
E 34 97% 82% (10d-6w)
Mallios
(2019)
E 34 97%
82% pr im
94% sec
Beathard
(2019)
E 105 Unkwn 100% 92.7% 24m, 
cum
Author (Year) Device # pts
Intervention rate 
(ppy)
Major
adverse 
event rate
Adverse events
Hull (2017) E 107 2.7 many
thrombosis, anast stenosis, 
steal, ven HTN, coil mig, vein 
rupture, neuropathy
Hebibi (2019) E 34 35% -- --
Mallios (2019) E 34 2.9% 0% --
Beathard (2019) E 105 -- -- --
Percutaneous AVF devices
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
VeinArtery
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices - WavelinQ
Post AVF creation
Percutaneous AVF devices - WavelinQ
Percutaneous AVF devices
Pre AVF creation
Percutaneous AVF devices - WavelinQ
Post AVF creation
Percutaneous AVF devices
Percutaneous AVF devices - Comparison
• Post balloon angioplasty to 5 mm
• Immediate tissue fusion
• Coil 1 brachial vein
• Endothelialized tract ~30d (48h)
Percutaneous AVF devices - WavelinQ
Author (Year) Device # pts
Technical 
success
Maturation 
90d
Median time to 
maturation
Mean time to 2 
needle cann
Patency
Use for 
>75% of 
sessions
Rajan (2015) W 33 97% 96%
58 d
(37-168 d)
-- 96% 6m
100%
Lok (2017) W 60 98% 87% --
111.8 d HD
32.4 d nonHD
84% 12m, cum --
Radosa 
(2017)
W 8 100% 86%
63 d 
(26-137 d)
-- 100% 6m 100%
Berland
(2019)
W 32 100% 91% -- 43 + 14 d 87% 6m, cum 74%
Hull (2017) E 107 95% 86% 114.3 d 86.7% 24m, 
cum
Hebibi
(2019)
E 34 97% 82% (10d-6w)
Mallios
(2019)
E 34 97%
82% pr im
94% sec
Beathard
(2019)
E 105 Unkwn 100% 92.7% 24m, 
cum
Author (Year) Device # pts
Intervention rate 
(ppy)
Major adverse 
event rate
Adverse events
Rajan (2015) W 33 0.1-0.6 3% (1) brachial artery PSA
Lok (2017) W 60 0.46 8% (5)
closure device embo, brach
art dissection and 
thrombus, PSA (access site, 
endoAVF site), steal 
syndrome
Radosa (2017) W 8 0.12 0% --
Berland (2019) W 32 0.21 3% (1)
guidewire perf tx’d w/ 
stenting
Hull (2017) E 107 2.7 many
thrombosis, anast stenosis, 
steal, ven HTN, coil mig, 
vein rupture, neuropathy
Hebibi (2019) E 34 35% -- --
Mallios (2019) E 34 2.9% 0% --
Beathard (2019) E 105 -- -- --
• Wee IJY, et al. J Vasc Surg (2020)
• Meta analysis
• WavelinQ and Ellipsys
• 300 patients
WavelinQ Ellipsys
Technical success 99.45% 95.19%
90 d maturation 89.27% 89.35%
6 mo patency 85.71% 90.98%
Procedure AE 8.59% 2.48%
Maturation→
Diameter >4 mm
Flow rate: >500 mL/min 
Candidates for pAVF
+ Perforator vein
No prior upper arm AVF creation
No flow limiting central stenosis
Vessel size at target creation site > 2 mm
No significant arterial calcification
Conscious sedation candidate
Percutaneous AVF devices
Candidates for pAVF
+ Perforator vein
No prior upper arm AVF creation
No flow limiting central stenosis
Vessel size at target creation site > 2 mm
No significant arterial calcification
Conscious sedation candidate
Percutaneous AVF devices
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Author 
(Year)
# pts
Technical 
success
Maturation 
90d
Median time 
to maturation
Mean time to 2 
needle cann
Patency
Use for 
>75% of 
sessions
Rajan
(2015)
33 97% 96%
58 d
(37-168 d)
-- 96% 6m
100%
Lok 
(2017)
60 98% 87% --
111.8 d HD
32.4 d nonHD
69% 12m, primary
84% 12m, cum
--
Radosa 
(2017)
8 100% 86%
63 d 
(26-137 d)
-- 100% 6m 100%
Berland 
(2019)
32 100% 91% -- 43 + 14 d 87% 6m, cum 74%
Surgical
AVFs
-- 93% 40-80%
159 d
(77-285 d)
60% 12m, pr imary
71% 12m, cum
Author (Year) # pts
Major adverse 
event rate
Intervention rate 
(ppy)
Interventions needed
Rajan (2015) 33 3% (1) 0.1-0.6 Brachial artery PSA
Lok (2017) 60 8% (5) 0.46
Closure device embo, 
brach art dissection and 
thrombus, PSA (access 
site, endoAVF site), Steal 
Syndrome
Radosa (2017) 8 0% 0.12 --
Berland (2019) 32 3% (1) 0.21
Guidewire perf tx’d w/ 
stenting
Surgical AVFs -- -- 1.5-3.3
Superficialization, 
angioplasty, stenting, 
revision, conversion to 
AVG, Steal syndrome, 
tributary ligation, 
thrombectomy, etc





